{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6"},{"groupId":"OG001","value":"0.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"320"},{"groupId":"OG001","value":"323"}],"units":"Participants"}],"description":"Participants who developed treatment-emergent antibody responses to Ramucirumab (IMC-1121B) after baseline.","groups":[{"description":"8 mg/kg of ramucirumab (IMC-1121B) was administered by IV infusion on Days 1 and 15 in combination with 80 mg/m² paclitaxel administered by IV infusion on Days 1, 8, and 15 of a 28-day cycle.","id":"OG000","title":"Ramucirumab (IMC-1211B) Plus Paclitaxel"},{"description":"Placebo was administered by IV infusion on Days 1 and 15, in combination with 80 mg/m² paclitaxel administered on Days 1, 8, and 15 of a 28-day cycle.","id":"OG001","title":"Placebo Plus Paclitaxel"}],"paramType":"NUMBER","populationDescription":"All participants according to the treatment group to which they were randomized and received at least 1 dose of study drug with anti-ramucirumab antibodies.","reportingStatus":"POSTED","timeFrame":"Prior to and after ramucirumab (IMC-1121B) infusion: Day 1 Cycles 1, 2 and 3 (28-day cycles) Doses 1, 4, 7 and 30-37 days after last dose of study therapy up to 103 weeks","title":"Percentage of Participants With Anti-Ramucirumab Antibodies (Serum Anti-Ramucirumab Antibody Assessment )(Immunogenicity)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}